OMERS ADMINISTRATION Corp Invests $342,000 in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

OMERS ADMINISTRATION Corp purchased a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,800 shares of the company's stock, valued at approximately $342,000. OMERS ADMINISTRATION Corp owned about 0.06% of Ginkgo Bioworks as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter worth $29,000. KBC Group NV purchased a new position in shares of Ginkgo Bioworks in the 4th quarter worth $31,000. KLP Kapitalforvaltning AS purchased a new position in shares of Ginkgo Bioworks in the 4th quarter worth $46,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Ginkgo Bioworks in the 4th quarter worth $116,000. Finally, Palumbo Wealth Management LLC purchased a new position in shares of Ginkgo Bioworks in the 4th quarter worth $144,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded up $0.14 during trading on Friday, hitting $6.99. The stock had a trading volume of 1,025,293 shares, compared to its average volume of 1,459,841. The firm's fifty day simple moving average is $7.21 and its 200-day simple moving average is $9.06. The stock has a market cap of $409.14 million, a PE ratio of -0.53 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $27.16.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.